MX2018008840A - Moleculas que activan selectivamente celulas t reguladoras para el tratamiento de enfermedades. - Google Patents
Moleculas que activan selectivamente celulas t reguladoras para el tratamiento de enfermedades.Info
- Publication number
- MX2018008840A MX2018008840A MX2018008840A MX2018008840A MX2018008840A MX 2018008840 A MX2018008840 A MX 2018008840A MX 2018008840 A MX2018008840 A MX 2018008840A MX 2018008840 A MX2018008840 A MX 2018008840A MX 2018008840 A MX2018008840 A MX 2018008840A
- Authority
- MX
- Mexico
- Prior art keywords
- molecules
- cells
- treatment
- autoimmune diseases
- selectively activate
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
Abstract
Esta invención provee una proteína de fusión entre una proteína de Agonista Selectivo de lL2aß? (agonista selectivo de IL2) y una proteína lgG Fc usando un enlazador. La porción de Agonista Selectivo de IL2 provee una actividad terapéutica al activar selectivamente la forma lL2aß? del receptor, estimulando así selectivamente Tregs. La porción Fc provee una vida media en circulación prolongada en comparación con la vida media en circulación de IL-2 o una proteína IL2SA.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/002,144 US20170204154A1 (en) | 2016-01-20 | 2016-01-20 | Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases |
PCT/US2017/014090 WO2017127514A1 (en) | 2016-01-20 | 2017-01-19 | Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2018008840A true MX2018008840A (es) | 2018-11-09 |
Family
ID=59314394
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2018008840A MX2018008840A (es) | 2016-01-20 | 2017-01-19 | Moleculas que activan selectivamente celulas t reguladoras para el tratamiento de enfermedades. |
Country Status (16)
Country | Link |
---|---|
US (7) | US20170204154A1 (es) |
EP (1) | EP3405482A4 (es) |
JP (2) | JP6983787B2 (es) |
KR (1) | KR20180100237A (es) |
CN (1) | CN108602871A (es) |
AU (2) | AU2017210187B2 (es) |
BR (1) | BR112018014671A2 (es) |
CA (1) | CA3010621A1 (es) |
CL (1) | CL2018001951A1 (es) |
CO (1) | CO2018008558A2 (es) |
EA (1) | EA201891656A1 (es) |
EC (1) | ECSP18062614A (es) |
MX (1) | MX2018008840A (es) |
SG (1) | SG11201805784PA (es) |
WO (1) | WO2017127514A1 (es) |
ZA (1) | ZA201804458B (es) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3587444A1 (en) * | 2014-07-21 | 2020-01-01 | Delinia, Inc. | Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases |
US20170204154A1 (en) * | 2016-01-20 | 2017-07-20 | Delinia, Inc. | Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases |
US11077172B2 (en) * | 2016-11-08 | 2021-08-03 | Delinia, Inc. | IL-2 variants for the treatment of psoriasis |
AU2018234810B2 (en) | 2017-03-15 | 2023-05-11 | Pandion Operations, Inc. | Targeted immunotolerance |
US11879014B2 (en) | 2017-03-17 | 2024-01-23 | Tusk Therapeutics Ltd. | Method of treating cancer or depleting regulatory T cells in a subject by administering a human IGG1 anti-CD25 antibody |
JOP20190271A1 (ar) | 2017-05-24 | 2019-11-21 | Novartis Ag | بروتينات مطعّمة بسيتوكين- الجسم المضاد وطرق الاستخدام للاضطرابات المتعلقة بالمناعة |
SG11201909949XA (en) | 2017-05-24 | 2019-11-28 | Pandion Therapeutics Inc | Targeted immunotolerance |
US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
US10174092B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
US20210260163A1 (en) * | 2018-03-09 | 2021-08-26 | AskGene Pharma, Inc. | Novel cytokine prodrugs |
CN112020515A (zh) | 2018-03-13 | 2020-12-01 | 塔斯克疗法有限公司 | 用于肿瘤特异性细胞清除的抗-cd25 |
AU2019244091B2 (en) | 2018-03-28 | 2023-12-07 | Bristol-Myers Squibb Company | Interleukin-2/Interleukin-2 receptor alpha fusion proteins and methods of use |
BR122021012517A2 (pt) | 2018-08-06 | 2021-08-10 | Medikine, Inc. | Ligante il-2rgamac, composto compreendendo referido ligante, composição farmacêutica e uso do referido ligante |
JP7479383B2 (ja) | 2018-09-27 | 2024-05-08 | エクシリオ デベロップメント, インコーポレイテッド | マスクされたサイトカインポリペプチド |
EP3873923A4 (en) * | 2018-10-31 | 2023-02-08 | Delinia, Inc. | MULTIVALENT REGULATORY T-CELL MODULATORS |
TW202110885A (zh) | 2019-05-20 | 2021-03-16 | 美商潘迪恩治療公司 | 靶向MAdCAM之免疫耐受性 |
KR20220020879A (ko) | 2019-06-12 | 2022-02-21 | 에스크진 파마, 아이엔씨. | 새로운 il-15 프로드럭 및 이를 사용하는 방법 |
KR20220044834A (ko) * | 2019-08-15 | 2022-04-11 | 사이팀 테라퓨틱스, 인크. | 변형된 인터루킨 2 (il-2) 폴리펩타이드, 컨쥬게이트 및 이의 용도 |
US20230057622A1 (en) * | 2019-09-16 | 2023-02-23 | Zensun (Shanghai) Science & Technology, Co., Ltd. | Recombinant Human Neuregulin Derivatives and Use Thereof |
US11248030B2 (en) | 2019-11-05 | 2022-02-15 | Medikine, Inc. | Dual IL-2R and IL-7R binding compounds |
BR112022008744A2 (pt) | 2019-11-05 | 2022-07-19 | Medikine Inc | Ligante de il-2rss, ligante de il-2r¿c, composto de ligação a il-2r¿¿c, composição farmacêutica, método para tratar uma doença em um paciente, método para expandir células imunes, método de uma terapia celular, método para reforçar uma vacina, método para modificar a resposta imune e ácido nucleico |
US20210187027A1 (en) | 2019-12-20 | 2021-06-24 | Regeneron Pharmaceuticals, Inc. | Novel il2 agonists and methods of use thereof |
AU2021206449A1 (en) | 2020-01-10 | 2022-07-21 | Bright Peak Therapeutics Ag | Modified IL-2 polypeptides and uses thereof |
JP2023512687A (ja) | 2020-02-03 | 2023-03-28 | メディカイン、インコーポレイテッド | IL-7Rα結合化合物 |
US11746139B2 (en) | 2020-02-03 | 2023-09-05 | Medikine, Inc. | IL-7Rαγc binding compounds |
EP4107187A1 (en) | 2020-02-21 | 2022-12-28 | Pandion Operations, Inc. | Tissue targeted immunotolerance with a cd39 effector |
JP2023526282A (ja) | 2020-05-13 | 2023-06-21 | ボナム セラピューティクス,インク. | タンパク質複合体の組成物及びその使用方法 |
TW202406932A (zh) | 2020-10-22 | 2024-02-16 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
WO2022094275A1 (en) | 2020-10-29 | 2022-05-05 | Bristol-Myers Squibb Company | Fusion proteins for the treatment of disease |
CN113789346A (zh) * | 2021-08-25 | 2021-12-14 | 北京伟德杰生物科技有限公司 | 长效化重组人白细胞介素2融合蛋白及其制备方法和应用 |
TW202400218A (zh) * | 2022-02-11 | 2024-01-01 | 美商威特拉公司 | 使用介白素-2(il-2)藥劑之方法 |
WO2024054868A1 (en) * | 2022-09-07 | 2024-03-14 | Xencor, Inc. | An il-2 fc fusion protein for use in methods for the treatment of plaque psoriasis and atopic dermatitis |
Family Cites Families (65)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4853332A (en) | 1982-10-19 | 1989-08-01 | Cetus Corporation | Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of biologically active proteins |
US5206344A (en) | 1985-06-26 | 1993-04-27 | Cetus Oncology Corporation | Interleukin-2 muteins and polymer conjugation thereof |
US5466447A (en) | 1988-06-29 | 1995-11-14 | Amgen Inc. | Method for treating psoriasis |
AU627477B2 (en) | 1988-07-05 | 1992-08-27 | Amgen, Inc. | Interleukin ii analogs |
US4902502A (en) | 1989-01-23 | 1990-02-20 | Cetus Corporation | Preparation of a polymer/interleukin-2 conjugate |
US5089261A (en) | 1989-01-23 | 1992-02-18 | Cetus Corporation | Preparation of a polymer/interleukin-2 conjugate |
US6541610B1 (en) | 1989-09-05 | 2003-04-01 | Immunex Corporation | Fusion proteins comprising tumor necrosis factor receptor |
US5650150A (en) | 1990-11-09 | 1997-07-22 | Gillies; Stephen D. | Recombinant antibody cytokine fusion proteins |
US5281698A (en) | 1991-07-23 | 1994-01-25 | Cetus Oncology Corporation | Preparation of an activated polymer ester for protein conjugation |
WO1995008340A1 (en) | 1993-09-21 | 1995-03-30 | Amgen Inc. | Method for treating psoriasis |
BR9908226A (pt) | 1998-02-25 | 2000-10-24 | Lexigen Pharm Corp | Melhoramento da meia vida de circulação de proteìnas de fusão com base em anticorpo |
FI104522B (fi) | 1998-04-28 | 2000-02-15 | Abb Control Oy | Kytkinvarokerunko |
US6955807B1 (en) | 1998-05-15 | 2005-10-18 | Bayer Pharmaceuticals Corporation | IL-2 selective agonists and antagonists |
DZ2788A1 (fr) | 1998-05-15 | 2003-12-01 | Bayer Ag | Agonistes et antagonistes selectifs à IL-2. |
US6348192B1 (en) | 1999-05-11 | 2002-02-19 | Bayer Corporation | Interleukin-2 mutein expressed from mammalian cells |
SK782002A3 (en) | 1999-07-21 | 2003-08-05 | Lexigen Pharm Corp | FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens |
WO2001062827A2 (en) | 2000-02-22 | 2001-08-30 | Shearwater Corporation | N-maleimidyl polymer derivatives |
US6689353B1 (en) | 2000-06-28 | 2004-02-10 | Bayer Pharmaceuticals Corporation | Stabilized interleukin 2 |
ATE427318T1 (de) | 2000-09-14 | 2009-04-15 | Beth Israel Hospital | Modulierung von il-2 und il-15 vermittelten t zellantworten |
PL206701B1 (pl) | 2001-03-07 | 2010-09-30 | Merck Patent Gmbh | Immunoglobulinowe białko fuzyjne, kodujący je kwas nukleinowy, replikujący wektor ekspresji zawierający taki kwas nukleinowy, eukariotyczna komórka gospodarza zawierająca taki wektor ekspresji oraz sposób zwiększania ekspresji takiego białka fuzyjnego |
DE60236522D1 (de) | 2001-07-11 | 2010-07-08 | Maxygen Inc | G-csf konjugate |
WO2003012036A2 (en) | 2001-07-27 | 2003-02-13 | The Government Of The United States Of America As Represented By The Secretary Of Health And Human Services | Systems for in vivo site-directed mutagenesis using oligonucleotides |
WO2003015697A2 (en) | 2001-08-13 | 2003-02-27 | University Of Southern California | Interleukin-2 mutants with reduced toxicity |
BR0214650A (pt) * | 2001-12-04 | 2005-05-03 | Merck Patent Gmbh | Imunocitoquinas com seletividade modulada |
US7452968B2 (en) | 2003-01-02 | 2008-11-18 | University Of Southern California | Secreted protein factor and cell membrane-bound splice variant |
AU2004251145C1 (en) | 2003-06-12 | 2011-04-14 | Eli Lilly And Company | GLP-1 analog fusion proteins |
US7569215B2 (en) | 2003-07-18 | 2009-08-04 | Massachusetts Institute Of Technology | Mutant interleukin-2 (IL-2) polypeptides |
ATE500267T1 (de) | 2003-07-21 | 2011-03-15 | Transgene Sa | Multifunktionelle cytokine |
JP2007500132A (ja) * | 2003-07-25 | 2007-01-11 | アムジェン インコーポレイテッド | Ldcamのアンタゴニストおよびアゴニスト、並びにその使用法 |
WO2005091956A2 (en) | 2004-03-05 | 2005-10-06 | Chiron Corporation | In vitro test system for predicting patient tolerability of therapeutic agents |
JP2008528621A (ja) | 2005-01-27 | 2008-07-31 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス インコーポレイテッド | 腎細胞ガンを処置するための方法 |
EP1688146B1 (en) | 2005-02-07 | 2007-07-18 | Novartis Vaccines and Diagnostics, Inc. | Preparing aldesleukin for pharmaceutical use |
BRPI0717431A2 (pt) * | 2006-09-29 | 2013-11-12 | Oncomed Pharm Inc | Composições e métodos de diagnóstico e tratamento do câncer |
FR2918770B1 (fr) | 2007-07-10 | 2009-09-11 | Essilor Int | Afficheur destine a etre integre a une paire de lunettes. |
US8906356B2 (en) | 2007-11-05 | 2014-12-09 | Massachusetts Institute Of Technology | Mutant interleukin-2 (IL-2) polypeptides |
DE102008023820A1 (de) | 2008-05-08 | 2009-11-12 | Aicuris Gmbh & Co. Kg | Mittel zur Behandlung und/oder Prophylaxe einer Autoimmunerkrankung und zur Bildung von Regulatorischen T-Zellen |
JP5766124B2 (ja) | 2009-01-21 | 2015-08-19 | アムジェン インコーポレイテッド | 炎症性疾患および自己免疫疾患の処置の組成物および方法 |
MA33198B1 (fr) | 2009-03-20 | 2012-04-02 | Genentech Inc | Anticorps anti-her di-spécifiques |
EP2443137B1 (en) * | 2009-06-15 | 2015-05-20 | Biokine Therapeutics Ltd. | Novel chemokine binding polypeptides capable of inhibiting the course of autoimmunity, inflammation and cancer |
EP2542590B2 (en) | 2010-03-05 | 2020-04-01 | The Johns Hopkins University | Compositions and methods for targeted immunomodulatory antibodies and fusion proteins |
KR102472497B1 (ko) | 2010-11-12 | 2022-11-29 | 넥타르 테라퓨틱스 | Il-2 부분 및 중합체의 접합체 |
CU23923B1 (es) | 2010-11-12 | 2013-07-31 | Ct De Inmunología Molecular | Polipéptidos derivados de la il-2 con actividad agonista |
CN102462837B (zh) | 2010-11-19 | 2016-08-03 | 生物林格斯Ip有限公司 | 抗炎组合物 |
EP3211001B1 (en) | 2010-12-22 | 2020-10-07 | The Board of Trustees of the Leland Stanford Junior University | Superagonists and antagonists of interleukin-2 |
CN102174111B (zh) | 2011-01-25 | 2013-01-09 | 江苏省弗泰生物科技有限公司 | 人白介素2-Fc融合蛋白及其用途 |
CN105440123B (zh) | 2011-02-10 | 2020-10-09 | 罗切格利卡特公司 | 突变体白介素-2多肽 |
ES2811624T3 (es) | 2011-03-11 | 2021-03-12 | Hopitaux Paris Assist Publique | Régimen de dosificación de IL-2 para tratar lupus eritematoso sistémico |
EA201892619A1 (ru) * | 2011-04-29 | 2019-04-30 | Роше Гликарт Аг | Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2 |
WO2013177187A2 (en) | 2012-05-22 | 2013-11-28 | Massachusetts Institute Of Technology | Synergistic tumor treatment with extended-pk il-2 and therapeutic agents |
US20140044675A1 (en) | 2012-08-10 | 2014-02-13 | Roche Glycart Ag | Interleukin-2 fusion proteins and uses thereof |
JP2014094898A (ja) * | 2012-11-07 | 2014-05-22 | Univ Of Tsukuba | 炎症性腸疾患に関連する、CD300a発現細胞の活性調節剤を含有する医薬品、ならびにCD300a遺伝子欠損マウスおよびCD300a発現細胞の活性調節剤の使用 |
US9580486B2 (en) | 2013-03-14 | 2017-02-28 | Amgen Inc. | Interleukin-2 muteins for the expansion of T-regulatory cells |
US10544187B2 (en) * | 2013-03-15 | 2020-01-28 | Xencor, Inc. | Targeting regulatory T cells with heterodimeric proteins |
CN103193887B (zh) | 2013-04-03 | 2015-02-04 | 江苏众红生物工程创药研究院有限公司 | 一种重组猪白细胞介素2-Fc融合蛋白及其编码基因和表达方法 |
US20150017120A1 (en) | 2013-06-13 | 2015-01-15 | Massachusetts Institute Of Technology | Synergistic tumor treatment with extended-pk il-2 and adoptive cell therapy |
EP3102595B1 (en) | 2014-02-06 | 2018-11-07 | F.Hoffmann-La Roche Ag | Interleukin-2 fusion proteins and uses thereof |
EP3134102B1 (en) | 2014-04-24 | 2019-07-03 | The Board of Trustees of The Leland Stanford Junior University | Superagonists, partial agonists and antagonists of interleukin-2 |
KR20150133576A (ko) | 2014-05-20 | 2015-11-30 | 삼성전자주식회사 | 화학적 개질된 표적화 단백질 및 그의 이용 |
EP3587444A1 (en) | 2014-07-21 | 2020-01-01 | Delinia, Inc. | Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases |
HUE051414T2 (hu) | 2014-08-11 | 2021-03-01 | Delinia Inc | Módosított IL-2 változatok, amelyek szelektíven aktiválnak regulátor T sejteket, autoimmun betegségek kezelésére |
US20170224777A1 (en) | 2014-08-12 | 2017-08-10 | Massachusetts Institute Of Technology | Synergistic tumor treatment with il-2, a therapeutic antibody, and a cancer vaccine |
JP6941561B2 (ja) | 2014-10-09 | 2021-09-29 | デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド | 免疫障害を処置するための複数の可変il−2用量レジメン |
US20170204154A1 (en) | 2016-01-20 | 2017-07-20 | Delinia, Inc. | Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases |
JP7422480B2 (ja) | 2016-05-04 | 2024-01-26 | アムジエン・インコーポレーテツド | 制御性t細胞の増殖のためのインターロイキン-2変異タンパク質 |
US11077172B2 (en) | 2016-11-08 | 2021-08-03 | Delinia, Inc. | IL-2 variants for the treatment of psoriasis |
-
2016
- 2016-01-20 US US15/002,144 patent/US20170204154A1/en not_active Abandoned
-
2017
- 2017-01-19 JP JP2018538769A patent/JP6983787B2/ja active Active
- 2017-01-19 SG SG11201805784PA patent/SG11201805784PA/en unknown
- 2017-01-19 WO PCT/US2017/014090 patent/WO2017127514A1/en active Application Filing
- 2017-01-19 BR BR112018014671A patent/BR112018014671A2/pt not_active Application Discontinuation
- 2017-01-19 AU AU2017210187A patent/AU2017210187B2/en active Active
- 2017-01-19 KR KR1020187023925A patent/KR20180100237A/ko not_active Application Discontinuation
- 2017-01-19 EP EP17741904.1A patent/EP3405482A4/en active Pending
- 2017-01-19 CA CA3010621A patent/CA3010621A1/en active Pending
- 2017-01-19 MX MX2018008840A patent/MX2018008840A/es unknown
- 2017-01-19 CN CN201780007419.1A patent/CN108602871A/zh active Pending
- 2017-01-19 EA EA201891656A patent/EA201891656A1/ru unknown
- 2017-09-06 US US15/696,811 patent/US10294287B2/en active Active
-
2018
- 2018-07-03 ZA ZA2018/04458A patent/ZA201804458B/en unknown
- 2018-07-19 CL CL2018001951A patent/CL2018001951A1/es unknown
- 2018-08-15 CO CONC2018/0008558A patent/CO2018008558A2/es unknown
- 2018-08-20 EC ECSENADI201862614A patent/ECSP18062614A/es unknown
-
2019
- 2019-02-05 US US16/267,583 patent/US10875901B2/en active Active
- 2019-03-13 US US16/352,249 patent/US10766938B2/en active Active
- 2019-03-13 US US16/352,003 patent/US10774126B2/en active Active
- 2019-12-30 US US16/729,698 patent/US11535657B2/en active Active
-
2020
- 2020-11-06 US US17/091,190 patent/US20210070828A1/en not_active Abandoned
-
2021
- 2021-10-26 AU AU2021257949A patent/AU2021257949A1/en not_active Abandoned
- 2021-11-24 JP JP2021189835A patent/JP2022058337A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
US10875901B2 (en) | 2020-12-29 |
US10766938B2 (en) | 2020-09-08 |
AU2021257949A1 (en) | 2021-11-25 |
JP2019507589A (ja) | 2019-03-22 |
US20190153058A1 (en) | 2019-05-23 |
AU2017210187A1 (en) | 2018-07-19 |
US20210070828A1 (en) | 2021-03-11 |
CN108602871A (zh) | 2018-09-28 |
AU2017210187B2 (en) | 2021-10-07 |
US20180037624A1 (en) | 2018-02-08 |
US20190202881A1 (en) | 2019-07-04 |
EP3405482A4 (en) | 2019-06-26 |
EP3405482A1 (en) | 2018-11-28 |
US20200115429A1 (en) | 2020-04-16 |
KR20180100237A (ko) | 2018-09-07 |
ECSP18062614A (es) | 2018-10-31 |
US20170204154A1 (en) | 2017-07-20 |
JP6983787B2 (ja) | 2021-12-17 |
JP2022058337A (ja) | 2022-04-12 |
US10774126B2 (en) | 2020-09-15 |
CA3010621A1 (en) | 2017-07-27 |
ZA201804458B (en) | 2019-09-25 |
EA201891656A1 (ru) | 2018-12-28 |
US10294287B2 (en) | 2019-05-21 |
BR112018014671A2 (pt) | 2018-12-11 |
CL2018001951A1 (es) | 2018-12-28 |
US20190202882A1 (en) | 2019-07-04 |
SG11201805784PA (en) | 2018-08-30 |
WO2017127514A1 (en) | 2017-07-27 |
US11535657B2 (en) | 2022-12-27 |
CO2018008558A2 (es) | 2018-08-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2018008840A (es) | Moleculas que activan selectivamente celulas t reguladoras para el tratamiento de enfermedades. | |
MX2021000083A (es) | Moleculas que activan selectivamente celulas t reguladoras para el tratamiento de enfermedades autoinmunes. | |
GB2564823A (en) | Compositions and methods for T-cell receptors reprogramming using fusion proteins | |
EA201991142A1 (ru) | Варианты il-2 для лечения аутоиммунных заболеваний | |
MX2020004206A (es) | Variantes il-2 modificadas que activan selectivamente celulas t reguladoras para el tratamiento de enfermedades autoinmunitarias. | |
MX2017014822A (es) | Composiciones y métodos para la reprogramación del tcr con proteínas de fusión. | |
PH12020500078A1 (en) | Anti-ctla-4 antibodies and uses thereof | |
MX2021002969A (es) | Proteinas de union a nkg2d, cd16, y egfr, ccr4 o pd-l1. | |
MX2021002970A (es) | Proteinas de union a nkg2d, cd16 y un antigeno asociado a tumor. | |
PH12021551439A1 (en) | Irreversible inhibitors of menin-mll interaction | |
BR112019024654A2 (pt) | proteína de ligação nkg2d, cd16 e ror1 ou ror2 | |
MX2018011035A (es) | Anticuerpos-anti-mica. | |
EP4273258A3 (en) | Proteins binding her2, nkg2d and cd16 | |
MX2016010953A (es) | Proteinas de fc multimericas. | |
AU2015255979B2 (en) | Using B-cell-targeting antigen IgG fusion as tolerogenic protein therapy for treating adverse immune responses | |
TN2018000021A1 (en) | ANTl-CD154 ANTIBODY HAVING IMPROVED BINDING, FUNCTIONAL AND SAFETY CHARACTERISTICS AND USE IN HUMAN IMMUNOTHERAPY. | |
MX2020007628A (es) | Composiciones y metodos de uso. | |
MX2019013995A (es) | Una proteína que se une a nkg2d, cd16 y un antígeno asociado a un tumor. | |
EA202090387A1 (ru) | Белки, связывающие nkg2d, cd16 и flt3 | |
JOP20220071A1 (ar) | سيتوكين مناعي يشمل معقد بروتين دايمري غير متجانس على أساس IL-15/IL-15Ra | |
MX2019009541A (es) | Proteinas que se unen a psma, nkg2d y cd16. | |
MX2019009847A (es) | Proteínas que se unen a cd123, nkg2d y cd16. | |
WO2019030757A8 (en) | Chimeric antigen receptor for her2/neu and t-cells expressing same | |
EA201890148A1 (ru) | Способ индукции раннего ответа т-клеток памяти противоопухолевой вакциной из коротких пептидов | |
MX2021012967A (es) | Anticuerpos y formulaciones de anti-cd38. |